And S-1 have been orally administered to KM12C-bearing nude rats (six rats/group) once every day for 14 consecutive days, and antitumor effect (A), body weight adjustments (B) as well as the alter of hematological parameters (WBc (C) and platelet count (D)) were evaluated. Values are mean sD for six nude rats. Abbreviations: DFP-11207, 5-chloro-2-(3-(3-(ethoxymethyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydopyrimidine-1-carbonyl)benzoyloxy)pyridine-4-yl-2,6-bis(propionyloxy)isonicotinate; S-1, tegafur-gimeracil-oteracil; WBC, white blood cell.However, to confirm the proof of no GI damage in drug-treated rats, a portion on the duodenum was evaluated histochemically as shown in Figure eight. Both DFP-11207 and S-1 did not lead to a extreme damage of mucosal cells inside the GI tract while tegafur plus gimeracil alone (S-1 with out oteracil) induced the damage of mucosal layer as shown in the rightsubmit your manuscript | www.dovepress.combottom panel. In an additional pathological study, tegafur plus gimeracil without having oteracil has also resulted in 5-FU-induced the GI harm as reported previously.16 These findings suggest that CTA released from DFP-11207 inside the GI mucosal cells prevents the danger from the 5-FU-induced GI toxicity via its inhibition of 5-FU phosphorylation.Drug Design and style, Improvement and Therapy 2017:DovepressDovepressDFP-11207, a brand new oral 5-FU prodrug with self-controlled toxicityFigure 8 histochemical evaluation of gi tissues (jejunum) in rats treated with every single 112.5 ol/kg of DFP-11207 and s-1. Notes: Portions of your jejunum in rats treated with DFP-11207 and s-1, respectively, were isolated and evaluated pathologically by h e stain. as control group showing 5-FU-induced GI harm, tegafur plus gimeracil alone was administered to rats as identical way. Magnification 0. Abbreviations: DFP-11207, 5-chloro-2-(3-(3-(ethoxymethyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydopyrimidine-1-carbonyl)benzoyloxy)pyridine-4-yl-2,6-bis(propionyloxy) isonicotinate; 5-FU, 5-fluorouracil; GI, gastrointestinal; S-1, tegafur-gimeracil-oteracil.antitumor activity of DFP-11207 compared with other antimetabolites on gi cancer xenografts in nude ratsAntitumor activity of DFP-11207 was additional evaluated in human colorectal (HT-29), gastric (MKN-45), and pancreatic (BxPC-3 and PANC-1) cancer xenografts in nude rats, and compared its efficacy with 5-FU (IP) or gemcitabine (intravenous [IV]) making use of maximum safety doses in the standard care drugs without the need of extreme decrease in body weights. As summarized in Table 2, DFP-11207 showed drastically higher antitumor activity with 50 five of tumor growth inhibition (TGI) against HT-29, MKN-45, and BxPC-3 tumor models compared with 30 TGI by 5-FU and gemcitabine, whereas each DFP-11207 and gemcitabine showed a reduce activity, 27 versus 23 within the PANC-1 tumor model.Exatecan Intermediate 1 Data Sheet These outcomes strongly help the notion that DFP-11207 could be a brand new version of clinically improvement candidates of 5-FUDrug Design, Improvement and Therapy 2017:derivatives for the treatment of human GI cancers without a burden of normally seen side effects such as GI toxicity and bone marrow suppression by existing standard care drugs, including 5-FU and gemcitabine.1,2,3,4-Tetrahydrobenzo[h]quinoline Chemscene DiscussionFor more than 50 years, 5-FU has been playing a essential part inside the systemic chemotherapy for sufferers with various cancer varieties, particularly GI cancers.PMID:24140575 Even so, remarkably unique from other cytotoxic drugs, 5-FU exerts its antitumor activity as well as toxic impact by means of an intracellular metabolism to kind its active n.
